Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression.

Leoni V, Long JD, Mills JA, Di Donato S, Paulsen JS; PREDICT-HD study group.

Neurobiol Dis. 2013 Jul;55:37-43. doi: 10.1016/j.nbd.2013.03.013. Epub 2013 Apr 1.

2.

Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease.

Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SM, Hobbs NZ, Mandelli ML, Grisoli M, Björkhem I, Cattaneo E, Di Donato S.

Brain. 2008 Nov;131(Pt 11):2851-9. doi: 10.1093/brain/awn212. Epub 2008 Sep 4.

PMID:
18772220
3.

Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease.

Solomon A, Leoni V, Kivipelto M, Besga A, Oksengård AR, Julin P, Svensson L, Wahlund LO, Andreasen N, Winblad B, Soininen H, Björkhem I.

Neurosci Lett. 2009 Oct 2;462(1):89-93. doi: 10.1016/j.neulet.2009.06.073. Epub 2009 Jun 26.

PMID:
19560513
4.

24S-hydroxycholesterol in plasma: a marker of cholesterol turnover in neurodegenerative diseases.

Leoni V, Caccia C.

Biochimie. 2013 Mar;95(3):595-612. doi: 10.1016/j.biochi.2012.09.025. Epub 2012 Oct 3. Review.

PMID:
23041502
5.

The impairment of cholesterol metabolism in Huntington disease.

Leoni V, Caccia C.

Biochim Biophys Acta. 2015 Aug;1851(8):1095-105. doi: 10.1016/j.bbalip.2014.12.018. Epub 2015 Jan 14. Review.

PMID:
25596342
6.

Oxysterols as biomarkers in neurodegenerative diseases.

Leoni V, Caccia C.

Chem Phys Lipids. 2011 Sep;164(6):515-24. doi: 10.1016/j.chemphyslip.2011.04.002. Epub 2011 Apr 16. Review.

PMID:
21515244
7.

Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment?

Leoni V, Shafaati M, Salomon A, Kivipelto M, Björkhem I, Wahlund LO.

Neurosci Lett. 2006 Apr 10-17;397(1-2):83-7. Epub 2006 Jan 6.

PMID:
16406316
8.

Study of cholesterol metabolism in Huntington's disease.

Leoni V, Caccia C.

Biochem Biophys Res Commun. 2014 Apr 11;446(3):697-701. doi: 10.1016/j.bbrc.2014.01.188. Epub 2014 Feb 10. Review.

PMID:
24525128
9.

Diagnostic use of cerebral and extracerebral oxysterols.

Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Björkhem I.

Clin Chem Lab Med. 2004 Feb;42(2):186-91.

PMID:
15061359
10.

Whole body cholesterol metabolism is impaired in Huntington's disease.

Leoni V, Mariotti C, Nanetti L, Salvatore E, Squitieri F, Bentivoglio AR, Bandettini di Poggio M, Piacentini S, Monza D, Valenza M, Cattaneo E, Di Donato S.

Neurosci Lett. 2011 May 2;494(3):245-9. doi: 10.1016/j.neulet.2011.03.025. Epub 2011 Mar 22. Erratum in: Neurosci Lett. 2011 Jul 8;498(2):171. Bandettini Del Poggio, M [corrected to Bandettini di Poggio, M].

PMID:
21406216
11.

Multivariate prediction of motor diagnosis in Huntington's disease: 12 years of PREDICT-HD.

Long JD, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group.

Mov Disord. 2015 Oct;30(12):1664-72. doi: 10.1002/mds.26364. Epub 2015 Sep 4.

12.

Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid.

Leoni V, Caccia C.

Biochem Pharmacol. 2013 Jul 1;86(1):26-36. doi: 10.1016/j.bcp.2013.03.015. Epub 2013 Mar 28. Review.

PMID:
23541982
13.

Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.

Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A, Feingold J, Rabier D, Durr A.

PLoS One. 2007 Jul 25;2(7):e647.

14.

Links between ApoE, brain cholesterol metabolism, tau and amyloid beta-peptide in patients with cognitive impairment.

Leoni V, Solomon A, Kivipelto M.

Biochem Soc Trans. 2010 Aug;38(4):1021-5. doi: 10.1042/BST0381021. Review.

PMID:
20658997
15.

Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.

Unschuld PG, Edden RA, Carass A, Liu X, Shanahan M, Wang X, Oishi K, Brandt J, Bassett SS, Redgrave GW, Margolis RL, van Zijl PC, Barker PB, Ross CA.

Mov Disord. 2012 Jun;27(7):895-902. doi: 10.1002/mds.25010. Epub 2012 May 30.

16.

Cognitive decline in prodromal Huntington Disease: implications for clinical trials.

Paulsen JS, Smith MM, Long JD; PREDICT HD investigators and Coordinators of the Huntington Study Group.

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1233-9. doi: 10.1136/jnnp-2013-305114. Epub 2013 Aug 2.

17.

24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia.

Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Björkhem I, von Bergmann K, Heun R.

J Psychiatr Res. 2002 Jan-Feb;36(1):27-32.

PMID:
11755458
18.

Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis.

van de Kraats C, Killestein J, Popescu V, Rijkers E, Vrenken H, Lütjohann D, Barkhof F, Polman CH, Teunissen CE.

Mult Scler. 2014 Apr;20(4):412-7. doi: 10.1177/1352458513499421. Epub 2013 Aug 19.

PMID:
23959711
19.

Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease.

Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, Maier W, Björkhem I, von Bergmann K, Heun R.

Neuroreport. 2000 Jun 26;11(9):1959-62.

PMID:
10884051

Supplemental Content

Support Center